<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Transl Androl Urol</journal-id><journal-id journal-id-type="iso-abbrev">Transl Androl Urol</journal-id><journal-id journal-id-type="publisher-id">TAU</journal-id><journal-title-group><journal-title>Translational Andrology and Urology</journal-title></journal-title-group><issn pub-type="epub">2223-4691</issn><publisher><publisher-name>AME Publishing Company</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4842534</article-id><article-id pub-id-type="publisher-id">tau-05-S1-AB206</article-id><article-id pub-id-type="doi">10.21037/tau.2016.s206</article-id><article-categories><subj-group subj-group-type="heading"><subject>Printed Abstracts</subject></subj-group></article-categories><title-group><article-title>AB206. Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Hui</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Xie</surname><given-names>Keji</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Chonghe</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Ping</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ou</surname><given-names>Rubiao</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zeng</surname><given-names>Jianweng</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Deng</surname><given-names>Xiangrong</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Liling</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Maping</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Qingqing</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Qiuling</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Jiebing</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Tanghai</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><aff><target id="aff1" target-type="aff"><sup>1</sup></target>Department of Urology, Guangdong Provincial Work Injury Rehabilitation Hospital and Jinan University, Guangzhou 510900, <country>China</country>; <target id="aff2" target-type="aff"><sup>2</sup></target>Department of Urology, Guangzhou First Municipal People&#x02019;s Hospital, Guangzhou 510180, <country>China</country>; <target id="aff3" target-type="aff"><sup>3</sup></target>Department of Urology, Qingyan City People&#x02019;s Hospital, Jinan University, Qingyan, <country>China</country></aff></contrib-group><pub-date pub-type="epub-ppub"><month>4</month><year>2016</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>4</month><year>2016</year></pub-date><volume>5</volume><issue>Suppl 1</issue><elocation-id>AB206</elocation-id><permissions><copyright-statement>2016 Translational Andrology and Urology. All rights reserved.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Translational Andrology and Urology.</copyright-holder></permissions><abstract><sec><title>Objective</title><p>To evaluate the effect and safety of trigonal injection of botulinum toxin A (BTX-A) for patients with neurological detrusor overactivity (NDO) with incontinence.</p></sec><sec><title>Methods</title><p>A prospective, multicenter, single-blind and randomized controlled trial (RCT) was conducted between June 2011 and June 2014. Spinal cord injury patients with urinary incontinence secondary to NDO were recruited. At a 1:1 ratio, patients randomly received 200 U BTX-A intradetrusor injections excluding the trigone (control group) or 160 U intradetrusor and 40 U intratrigonal injections (experimental group). Patients were evaluated at baseline, and 4, 12 weeks after injection. The efficacy and safety outcomes included I-QoL, voiding volume, urinary incontinence episodes, complete dryness, maximum detrusor pressure (Pdetmax), volume at first involuntary detrusor contraction (VFIDC). Vesicoureteral reflux (VUR) and other adverse events were recorded.</p></sec><sec><title>Results</title><p>Ninety-six patients were recruited and 91 of them completed the trial. Among the 91 patients, 47 were randomized to experimental group and 44 to the control group. There were no significant differences in baseline evaluation items (gender, age, duration of spinal cord injury, level of neurological injury, AIS scores) between the two groups. At 12 weeks, the improvement was significantly better in the experimental group than in the control group for I-QoL (26.01 <italic>vs.</italic> 18.75, P=0.01), mean urinary incontinence episodes (&#x02212;5.22/d <italic>vs.</italic> &#x02212;4.68/d, P=0.01), complete dryness (13 <italic>vs.</italic> 5, P=0.03), mean voiding volume (159.72 <italic>vs.</italic> 139.07 mL, P=0.02), Pdetmax (&#x02212;33.34 <italic>vs</italic>. &#x02212;28.02 cmH<sub>2</sub>O, P=0.04), and VFIDC (106.81 <italic>vs.</italic> 97.86 mL, P=0.02), duration of first detrusor contraction (&#x02212;41.54 <italic>vs</italic>. &#x02212;18.65 s, P=0.03) and the number of patients with detrusor contraction (&#x02212;20 <italic>vs.</italic> &#x02212;9, P=0.02). In both of two groups, no patients developed VUR.</p></sec><sec><title>Conclusions</title><p>BTX-A intradetrusor and intratrigonal injections are more effective than those excluding the trigone for patients with NDO with incontinence. Intratrigonal injections do not induce VUR.</p></sec></abstract><kwd-group kwd-group-type="author"><title>Keywords: </title><kwd>Bladder trigone</kwd><kwd>botulinum toxin A (BTX-A)</kwd><kwd>neurological detrusor overactivity (NDO)</kwd><kwd>effect</kwd><kwd>safety</kwd><kwd>neurologic bladder</kwd></kwd-group></article-meta></front></article>